Previous Close | 0.5700 |
Open | 0.5700 |
Bid | 0.5605 x 100 |
Ask | 0.5810 x 100 |
Day's Range | 0.5611 - 0.5900 |
52 Week Range | 0.4950 - 2.6000 |
Volume | |
Avg. Volume | 182,036 |
Market Cap | 15.663M |
Beta (5Y Monthly) | 0.25 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.7600 |
Earnings Date | Dec 12, 2024 - Dec 16, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.97 |
VICTORIA, British Columbia, October 10, 2024--ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today celebrates the recent Nobel Prize in Chemistry awarded to David Baker of the University of Washington, Seattle, WA, USA, "for computational protein design," and jointly to Demis Hassabis and John M. Jumper of Google DeepMind, London, UK, "for protein structure prediction." This accolade highlights the vital role of
ImmunoPrecise Antibodies Ltd (IPA) reports a 19% revenue increase and significant cash burn reduction, while navigating profitability pressures and market valuation disconnects.